Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus.
Aug 26, 2013
Overview:Background Patients with diabetes mellitus are considered a high risk group for of adverse cardiac events even in the absence of overt myocardial ischemia or scar compared with patients without diabetes mellitus. Impaired coronary vascular function is an early manifestation... more
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Aug 11, 2014
Overview:Background and knowledge gap In a phase II trial, patients with proximal DVT were randomized to a 3-month course of treatment with apixaban or to conventional anticoagulant therapy with LMWH or fondaparinux followed by a vitamin K antagonist. The composite... more
Chagas Cardiomyopathy: The New Roadmap of International Scientific Organizations
Nov 30, 2018
Overview: By Alvaro Sosa Liprandi* Chagas Heart Disease (CHHD) is a preventable chronic non-communicable condition that mainly affects the poorest and most vulnerable population of Latin America. Driven by poverty, poor access to health services and other health system weaknesses, the... more
Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis.
Dec 12, 2013
Overview:Background and objectives: HF is a growing public health problem worldwide, and it is associated with an increased risk of left ventricular thrombus formation and cerebral embolism due to endothelial dysfunction, reduced blood flow and underlying state of hypercoagulability2-5. In... more
Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina
Feb 20, 2014
Overview:Background and objectives: Coronary heart disease (CHD) is the most common cause of death (and premature death) in the United Kingdom (UK) with 94,000 deaths from CHD in the UK each year (1 in 5 men and 1 in 7... more
Updated Clinical Classification of Pulmonary Hypertension
Mar 31, 2014
Overview:Methods The World Symposium on Pulmonary Hypertension (WSPH) convenes every 5 years to discuss updates in the field. The symposium is designed to create guidelines to improve clinical practice and to standardize both pathologic and clinical definitions. A consensus on... more
Proton Pump Inhibitors (PPI) with clopidogrel
May 02, 2012
Overview:A randomized, 2-Period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers Background The co-administration of proton pump inhibitors (PPI) with clopidogrel reduces the risk... more
The EMA approves ivabradine for the treatment of chronic heart failure
Apr 28, 2017
Overview:By Professor Juan Tamargo, Madrid, Spain The European Medicines Agency (EMA) has approved ivabradine for the treatment of chronic heart failure. This drug was licensed for stable angina since 2006. The EMA indicated that ivabradine it is suitable for patients... more
Psychotropic medications and the risk of sudden cardiac death during an acute coronary event.
May 02, 2012
Overview:Background Mental disorders have been associated with increased risk of cardiovascular (CV) mortality, and specifically with occurrence of sudden cardiac death (SCD). There is also growing evidence that psychotropic drugs could increase the risk of SCD. Knowledge Gap At present... more
Personalised antiplatelet therapy in stent thrombosis
May 16, 2012
Overview:Observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry Background Previous studies have demonstrated significant heterogeneity in responses to APT, and high residual platelet reactivity is associated with the risk of ischaemic events, including ST. Knowledge Gap The clinical impact... more